REGN logo

REGN Total liabilities

annual total liabilities:

$8.41B+$1.30B(+18.27%)
December 31, 2024

Summary

  • As of today (May 29, 2025), REGN annual total liabilities is $8.41 billion, with the most recent change of +$1.30 billion (+18.27%) on December 31, 2024.
  • During the last 3 years, REGN annual total liabilities has risen by +$1.74 billion (+26.10%).
  • REGN annual total liabilities is now at all-time high.

Performance

REGN Total liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNbalance sheet metrics

quarterly total liabilities:

$8.16B-$248.20M(-2.95%)
March 31, 2025

Summary

  • As of today (May 29, 2025), REGN quarterly total liabilities is $8.16 billion, with the most recent change of -$248.20 million (-2.95%) on March 31, 2025.
  • Over the past year, REGN quarterly total liabilities has increased by +$779.10 million (+10.56%).
  • REGN quarterly total liabilities is now -2.95% below its all-time high of $8.41 billion, reached on December 31, 2024.

Performance

REGN quarterly total liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNbalance sheet metrics

Total liabilities Formula

Total Liabilities = Current Liabilities + Long-Term Liabilities

REGN Total liabilities Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+18.3%+10.6%
3 y3 years+26.1%+26.8%
5 y5 years+126.2%+125.1%

REGN Total liabilities Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+28.3%-3.0%+30.8%
5 y5-yearat high+126.2%-3.0%+125.1%
alltimeall timeat high>+9999.0%-3.0%>+9999.0%

REGN Total liabilities History

DateAnnualQuarterly
Mar 2025
-
$8.16B(-3.0%)
Dec 2024
$8.41B(+18.3%)
$8.41B(+3.6%)
Sep 2024
-
$8.12B(+3.0%)
Jun 2024
-
$7.88B(+6.8%)
Mar 2024
-
$7.38B(+3.8%)
Dec 2023
$7.11B(+8.5%)
$7.11B(-2.1%)
Sep 2023
-
$7.26B(+9.3%)
Jun 2023
-
$6.64B(+1.1%)
Mar 2023
-
$6.56B(+0.2%)
Dec 2022
$6.55B(-1.7%)
$6.55B(+5.0%)
Sep 2022
-
$6.24B(-4.3%)
Jun 2022
-
$6.52B(+1.3%)
Mar 2022
-
$6.43B(-3.5%)
Dec 2021
$6.67B(+8.6%)
$6.67B(+3.9%)
Sep 2021
-
$6.41B(+0.9%)
Jun 2021
-
$6.36B(+9.7%)
Mar 2021
-
$5.80B(-5.6%)
Dec 2020
$6.14B(+65.2%)
$6.14B(+3.0%)
Sep 2020
-
$5.96B(+10.9%)
Jun 2020
-
$5.37B(+48.2%)
Mar 2020
-
$3.62B(-2.4%)
Dec 2019
$3.72B(+24.8%)
$3.72B(+8.2%)
Sep 2019
-
$3.43B(+0.5%)
Jun 2019
-
$3.42B(+0.2%)
Mar 2019
-
$3.41B(+14.5%)
Dec 2018
$2.98B(+13.6%)
$2.98B(+1.4%)
Sep 2018
-
$2.94B(+6.2%)
Jun 2018
-
$2.77B(-1.4%)
Mar 2018
-
$2.81B(+7.1%)
Dec 2017
$2.62B(+3.8%)
$2.62B(-1.1%)
Sep 2017
-
$2.65B(+2.5%)
Jun 2017
-
$2.59B(-12.4%)
Mar 2017
-
$2.95B(+16.9%)
Dec 2016
$2.52B(+29.2%)
$2.52B(+8.0%)
Sep 2016
-
$2.34B(+9.8%)
Jun 2016
-
$2.13B(-0.5%)
Mar 2016
-
$2.14B(+9.5%)
Dec 2015
$1.95B(+51.8%)
$1.95B(+3.6%)
Sep 2015
-
$1.89B(+58.7%)
Jun 2015
-
$1.19B(-3.1%)
Mar 2015
-
$1.23B(-4.7%)
Dec 2014
$1.29B(+28.9%)
$1.29B(+8.4%)
Sep 2014
-
$1.19B(+9.2%)
Jun 2014
-
$1.09B(+3.6%)
Mar 2014
-
$1.05B(+5.0%)
Dec 2013
$998.94M(+19.6%)
$998.94M(+5.1%)
Sep 2013
-
$950.24M(+7.4%)
Jun 2013
-
$884.92M(+1.8%)
Mar 2013
-
$869.65M(+4.1%)
Dec 2012
$835.11M(-0.3%)
$835.11M(-2.3%)
Sep 2012
-
$854.59M(-1.0%)
Jun 2012
-
$862.84M(+2.0%)
Mar 2012
-
$846.13M(+1.0%)
Dec 2011
$837.85M(+49.2%)
$837.85M(+51.0%)
Sep 2011
-
$554.78M(-2.5%)
Jun 2011
-
$568.83M(+2.3%)
Mar 2011
-
$556.20M(-1.0%)
Dec 2010
$561.62M(+63.1%)
$561.62M(-5.5%)
Sep 2010
-
$594.37M(+41.7%)
Jun 2010
-
$419.43M(+4.6%)
Mar 2010
-
$400.88M(+16.4%)
Dec 2009
$344.44M(+13.8%)
$344.44M(+7.7%)
Sep 2009
-
$319.75M(-3.6%)
Jun 2009
-
$331.84M(+22.4%)
Mar 2009
-
$271.10M(-10.4%)
Dec 2008
$302.71M
$302.71M(-22.2%)
Sep 2008
-
$388.96M(-2.8%)
Jun 2008
-
$400.23M(-14.9%)
DateAnnualQuarterly
Mar 2008
-
$470.27M(-1.2%)
Dec 2007
$475.99M(+29.2%)
$475.99M(+12.9%)
Sep 2007
-
$421.70M(+0.8%)
Jun 2007
-
$418.52M(+3.4%)
Mar 2007
-
$404.74M(+9.8%)
Dec 2006
$368.47M(+19.1%)
$368.47M(+25.9%)
Sep 2006
-
$292.71M(-0.6%)
Jun 2006
-
$294.56M(-1.7%)
Mar 2006
-
$299.77M(-3.1%)
Dec 2005
$309.50M(+6.5%)
$309.50M(+9.4%)
Sep 2005
-
$282.89M(+0.4%)
Jun 2005
-
$281.89M(-0.9%)
Mar 2005
-
$284.51M(-2.1%)
Dec 2004
$290.56M(-15.0%)
$290.56M(-1.1%)
Sep 2004
-
$293.81M(-1.4%)
Jun 2004
-
$298.04M(-1.3%)
Mar 2004
-
$302.07M(-11.7%)
Dec 2003
$341.91M(+39.2%)
$341.91M(-0.7%)
Sep 2003
-
$344.30M(+33.6%)
Jun 2003
-
$257.70M(-2.7%)
Mar 2003
-
$264.83M(+7.8%)
Dec 2002
$245.59M(+7.2%)
$245.59M(+3.3%)
Sep 2002
-
$237.80M(+4.6%)
Jun 2002
-
$227.29M(-0.9%)
Mar 2002
-
$229.38M(+0.1%)
Dec 2001
$229.04M(+776.1%)
$229.04M(+864.7%)
Sep 2001
-
$23.74M(+3.2%)
Jun 2001
-
$23.00M(-7.2%)
Mar 2001
-
$24.77M(-5.2%)
Dec 2000
$26.14M(-4.9%)
$26.14M(+3.1%)
Sep 2000
-
$25.35M(-3.1%)
Jun 2000
-
$26.15M(-1.1%)
Mar 2000
-
$26.44M(-3.9%)
Dec 1999
$27.50M(+7.0%)
$27.50M(+15.1%)
Sep 1999
-
$23.90M(-2.0%)
Jun 1999
-
$24.40M(-5.8%)
Mar 1999
-
$25.90M(+0.8%)
Dec 1998
$25.70M(-12.9%)
$25.70M(+0.8%)
Sep 1998
-
$25.50M(-6.6%)
Jun 1998
-
$27.30M(+5.0%)
Mar 1998
-
$26.00M(-11.9%)
Dec 1997
$29.50M(-3.9%)
$29.50M(+11.3%)
Sep 1997
-
$26.50M(-12.0%)
Jun 1997
-
$30.10M(+7.1%)
Mar 1997
-
$28.10M(-8.5%)
Dec 1996
$30.70M(+18.5%)
$30.70M(+16.3%)
Sep 1996
-
$26.40M(-0.4%)
Jun 1996
-
$26.50M(+10.0%)
Mar 1996
-
$24.10M(-6.9%)
Dec 1995
$25.90M(-4.4%)
$25.90M(+22.2%)
Sep 1995
-
$21.20M(-11.7%)
Jun 1995
-
$24.00M(+7.6%)
Mar 1995
-
$22.30M(-17.7%)
Dec 1994
$27.10M(+41.1%)
$27.10M(+10.2%)
Sep 1994
-
$24.60M(-15.5%)
Jun 1994
-
$29.10M(+50.8%)
Mar 1994
-
$19.30M(+0.5%)
Dec 1993
$19.20M(+79.4%)
$19.20M(+21.5%)
Sep 1993
-
$15.80M(+12.9%)
Jun 1993
-
$14.00M(+9.4%)
Mar 1993
-
$12.80M(+19.6%)
Dec 1992
$10.70M(+37.2%)
$10.70M(-1.8%)
Sep 1992
-
$10.90M(+16.0%)
Jun 1992
-
$9.40M(+2.2%)
Mar 1992
-
$9.20M(+17.9%)
Dec 1991
$7.80M(-40.9%)
$7.80M(+39.3%)
Sep 1991
-
$5.60M(-5.1%)
Jun 1991
-
$5.90M(-55.3%)
Dec 1990
$13.20M
$13.20M

FAQ

  • What is Regeneron Pharmaceuticals annual total liabilities?
  • What is the all time high annual total liabilities for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals annual total liabilities year-on-year change?
  • What is Regeneron Pharmaceuticals quarterly total liabilities?
  • What is the all time high quarterly total liabilities for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals quarterly total liabilities year-on-year change?

What is Regeneron Pharmaceuticals annual total liabilities?

The current annual total liabilities of REGN is $8.41B

What is the all time high annual total liabilities for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high annual total liabilities is $8.41B

What is Regeneron Pharmaceuticals annual total liabilities year-on-year change?

Over the past year, REGN annual total liabilities has changed by +$1.30B (+18.27%)

What is Regeneron Pharmaceuticals quarterly total liabilities?

The current quarterly total liabilities of REGN is $8.16B

What is the all time high quarterly total liabilities for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high quarterly total liabilities is $8.41B

What is Regeneron Pharmaceuticals quarterly total liabilities year-on-year change?

Over the past year, REGN quarterly total liabilities has changed by +$779.10M (+10.56%)
On this page